Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model

Blood

Volumn 117, Issue 5, 2011, Pages 1641-1651

  Gunn, W Grady ^a   Krause, Ulf ^b   Lee, Narae ^a   Gregory, Carl A ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 BROMOINDIRUBIN 3' OXIME; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; INDIRUBIN; OXIME DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE DESTRUCTION; BONE DISEASE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA BONE DISEASE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR NECROSIS; XENOGRAFT;

EID: 79551617573     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-308171     Document Type: Article

References (50)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516- 2520.
2. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50(1):29-40.
3. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860-1867. (Pubitemid 47557312)
4. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349(26):2483-2494. (Pubitemid 38010074)
5. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2006;24(4):986-991.
6. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone. 2008;42(4):669-680.
7. Qiang YW, Chen Y, Stephens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood. 2008;112(1):196-207.
8. Epstein J, Walker R. Myeloma and bone disease: "the dangerous tango". Clin Adv Hematol Oncol. 2006;4(4):300-306.
9. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20(17):3719-3736.
10. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005;106(9):3160-3165.
11. Qian J, Xie J, Hong S, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007;110(5):1587-1594.
12. Burger R, Guenther A, Bakker F, et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J. 2001;2(1):42-53. (Pubitemid 32266385)
13. Arnulf B, Lecourt S, Soulier J, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia. 2007;21(1):158-163.
14. Corre J, Mahtouk K, Attal M, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007;21(5):1079-1088.
15. Garderet L, Mazurier C, Chapel A, et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma. 2007;48(10):2032-2041.
16. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003;116(Pt 13):2627-2634.
17. Gregory CA, Green A, Lee N, Rao A, Gunn W. The promise of canonical Wnt signaling modulators in enhancing bone repair. Drug News Perspect. 2006;19(8):445-452.
18. Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24(3):425-436.
19. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109(5):2106-2111. (Pubitemid 46348212)
20. Fedi P, Bafico A, Nieto Soria A, et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem. 1999;274(27):19465-19472.
21. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391(6665):357-362.
22. Bain G, Muller T, Wang X, Papkoff J. Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun. 2003;301(1):84-91.
23. Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A. 2005;102(9):3324-3329.
24. Clement-Lacroix P, Ai M, Morvan F, et al. Lrp5- independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A. 2005; 102(48):17406-17411.
25. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513-523.
26. Kulkarni NH, Onyia JE, Zeng Q, et al. Orally bio-available GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res. 2006;21(6):910-920.
27. Krause U, Harris S, Green A, et al. Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci U S A. 2010;107(9):4147-4152.
28. Derksen PW, Tjin E, Meijer HP, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A. 2004;101(16):6122-6127.
29. Edwards CM, Edwards JR, Lwin ST, et al. Increasing Wnt signaling in the bone marrow micro-environment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood. 2008;111(5):2833-2842.
30. Chebel A, Kagialis-Girard S, Catallo R, et al. Indirubin derivatives inhibit malignant lymphoid cell proliferation. Leuk Lymphoma. 2009;50(12):2049-2060.
31. Zhou Y, Uddin S, Zimmerman T, Kang JA, Ulaszek J, Wickrema A. Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma. 2008;49(10):1945-1953.
32. Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L. Anti-mitotic properties of indirubin-3′- monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene. 2001;20(29):3786-3797.
33. Lee N, Smolarz AJ, Olson S, et al. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer. 2007;97(11):1552-1559.
34. Fulciniti M, Tassone P, Hideshima T, et al. Anti- DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114(2):371-379.
35. Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999;1(1):60-67.
36. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12(22):3499-3511.
37. Ghosh JC, Altieri DC. Activation of p53- dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res. 2005;11(12):4580-4588.
38. Zeng FY, Dong H, Cui J, Liu L, Chen T. Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells. Biochem Biophys Res Commun. 2010;391(1):1049-1055.
39. Ji XJ, Zhang FR, Lei JL, Xu YT. [Studies on the antineoplastic action and toxicity of synthetic indirubin (author's transl)]. Yao Xue Xue Bao. 1981;16(2):146-148.
40. Vestergaard P, Rejnmark L, Mosekilde L. Reduced relative risk of fractures among users of lithium. Calcif Tissue Int. 2005;77(1):1-8. (Pubitemid 41504166)
41. Qiang YW, Shaughnessy JD Jr, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood. 2008;112(2):374-382.
42. Croese JW, Vas Nunes CM, Radl J, van den Enden-Vieveen MH, Brondijk RJ, Boersma WJ. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br J Cancer. 1987;56(5):555-560.
43. Miyakawa Y, Ohnishi Y, Tomisawa M, et al. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun. 2004;313(2):258-262.
44. Tsunenari T, Koishihara Y, Nakamura A, et al. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood. 1997;90(6):2437-2444.
45. Epstein J, Yaccoby S. The SCID-hu myeloma model. Methods Mol Med. 2005;113:183-190.
46. Labrinidis A, Diamond P, Martin S, et al. Apo2L/ TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res. 2009;15(6):1998-2009.
47. Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia. 2007; 21(12):2527-2536.
48. Jost E, Gezer D, Wilop S, et al. Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma. Cancer Lett. 2009;281(1):24-31.
49. Sukhdeo K, Mani M, Zhang Y, et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A. 2007;104(18):7516-7521.
50. Qiang YW, Chen Y, Brown N, et al. Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma. Br J Haematol. 2010;148(5):726-738.